When EMA and FDA decisions conflict: differences in patients or in regulation?

@article{Wolfe2013WhenEA,
  title={When EMA and FDA decisions conflict: differences in patients or in regulation?},
  author={S. Wolfe},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
  • S. Wolfe
  • Published 2013
  • Medicine
  • BMJ : British Medical Journal
    • In his new regular column Sid Wolfe asks why the two regulatory bodies have arrived at different decisions on the same diet drugs 
    View on BMJ
    ncbi.nlm.nih.gov
    13 Citations
    Background Citations
    3
    13 Citations
    Citation Type

    Citation Type

    Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    • 19
    A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs
    • 9
    Illicit Internet availability of drugs subject to recall and patient safety consequences
    • 13
    Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
    • 83
    Horizons in the Pharmacotherapy of Obesity
    • 11
    • PDF
    Medications for the treatment of obesity in adolescents
    Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy
    • 10
    Current Perspectives on Long-term Obesity Pharmacotherapy.
    • S. Wharton
    • Medicine
    • Canadian journal of diabetes
    • 2016
    • 15
    Capsaicinoids : a potential role for weight management
    • PDF
    Pharmacotherapy for weight loss
    • 8

    References

    SHOWING 1-10 OF 12 REFERENCES
    Withdrawal of sibutramine in Europe
    • 64
    European regulatory body recommends suspension of rosiglitazone
    • D. Cohen
    • Medicine
    • BMJ : British Medical Journal
    • 2010
    • 8
    Elevated heart rate: a "new" cardiovascular risk factor?
    • P. Palatini
    • Medicine
    • Progress in cardiovascular diseases
    • 2009
    • 81
    FDA approves Belviq to treat some overweight or obese adults.
    • Medicine
    • Home healthcare nurse
    • 2012
    • 32
    22529: lorcaserin hydrochloride tablets, 10 mg [FDA briefing document for 10 May 2012 advisory committee meeting
      Advisory Committee meeting for phentermine/topiramate (Qnexa) [briefing memo
        Application number 022529Orig1s000: approval letter
          Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee meeting
            FDA approves weight-management drug Qsymia
              Medications target long-term weight control